Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
3 More Mid-Cap Biotechs The Street Sees Doubling
08:46am, Wednesday, 22'nd Feb 2023
Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the
Better Buy: Beam Therapeutics or Intellia Therapeutics?
06:00am, Wednesday, 22'nd Feb 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Market Insanity: Buying Stocks at 100 Times Revenue
10:44am, Monday, 20'th Feb 2023
There are no sure things in the stock market. But here's an almost sure thing: Investing in stocks that sell for 100 times revenue will lead you to grief.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
07:30am, Thursday, 16'th Feb 2023
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
05:52am, Tuesday, 07'th Feb 2023
These stocks are risky. But they just might deliver huge gains if analysts are right.
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
05:55am, Monday, 06'th Feb 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
03:48pm, Friday, 03'rd Feb 2023
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later
05:20pm, Wednesday, 25'th Jan 2023
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editin
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:45am, Tuesday, 24'th Jan 2023
The growth-focused money manager is making moves.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
10:50pm, Monday, 09'th Jan 2023
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
10 Potential 10x Return Stocks For The Next 10 Years
11:04am, Wednesday, 04'th Jan 2023
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or i
Intellia: In-Vivo Gene Editing Platform Continues To Deliver
08:25am, Tuesday, 20'th Dec 2022
In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR, respectively. Company has already gained the int
Intellia: Most Advanced In A Tough Field
07:57am, Tuesday, 20'th Dec 2022
Intellia is the first to show data in a tough field of medicine. The one-off offering has a sound attractiveness to it.
Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?
08:00am, Monday, 19'th Dec 2022
Intellia Therapeutic's stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of 31% in a month, while it's down 69% this year.
